Novo Nordisk narrowed its earnings guidance as intensifying competition, pricing pressure and copycat versions of its ...

Yahoo Finance Senior Reporter Allie Canal takes a closer look at some of Wednesday's trending tickers, including Novo Nordisk ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Pfizer and Novo Nordisk continue to fight for ownership of obesity startup Metsera; CDER Director George Tidmarsh leaves his ...

The latest of those is a bid valued at up to $10 billion for U.S. obesity-drug developer Metsera, up from a previous $9 billion offer it originally made, as it tries to usurp an already agreed-on deal ...

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...

Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the ...

The Dow, S&P 500, and Nasdaq are falling little changed as the stock market digests yesterday's tech-led selloff.

Healthy people who suffer traumatic spinal injuries are at significantly greater risk for long-term chronic health conditions ...

The FDA in September approved elamipretide (Forzinity) as the first treatment for the ultra-rare Barth syndrome despite ...